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We have approached the development of a human immunodeficiency virus type 1 (HIV-1) therapeutic
product by producing immune cells stably resistant to HIV-1. Promonocytic CD41 cells (U937) were made
resistant to HIV-1 by the introduction of a DNA construct (pNDU1A,B,C) that contained three independent
antisense sequences directed against two functional regions, transactivation response and tat/rev, of the HIV-1
target. Each sequence was incorporated into the transcribed region of a U1 snRNA gene to generate U1/HIV
antisense RNA. Stably transfected cells expressed all three U1/HIV antisense transcripts, and these transcripts
accumulated in the nucleus. These cells were subjected to two successive challenges with HIV-1 (BAL strain).
The surviving cells showed normal growth characteristics and have retained their CD41 phenotype. In situ
hybridization assays showed that essentially all of the surviving cells produced U1/HIV antisense RNA. No
detectable p24 antigen was observed, no syncytium formation was observed, and PCR-amplified HIV gag
sequences were not detected. Rechallenge with HIV-1 (IIIB strain) similarly yielded no infection at a relatively
high multiplicity of infection. As a further demonstration that the antisense RNA directed against HIV-1 was
functioning in these transfected immune cells, Tat-activated expression of chloramphenicol acetyltransferase
was shown to be specifically inhibited in cells expressing Tat and transactivation response region antisense
sequences.
The incidence of human immunodeficiency virus (HIV) in-
fection has reached alarmingly high levels worldwide, prompt-
ing efforts to develop effective treatments. Much of the devel-
opment has focused on an antiviral drug-based approach
designed for the most part to slow viral growth. We have
approached the development of an effective therapeutic prod-
uct by focusing on rendering the immune cells refractory to
HIV type 1 (HIV-1) infection. This will permit reconstitution
of a population of immune cells in the presence of HIV-1 and
may act to restore immunocompetence. This treatment can be
implemented by ex vivo treatment of hematopoietic stem cells
to add specific genetic material (4, 13).
As a means of inducing resistance to HIV-1, monocytic cells
in culture were transfected with a DNA construct expressing
three different sequences, each directed against a critical
HIV-1 target sequence. This multitargeting approach was used
in order to combat the high rate of variability and mutability of
HIV-1 that often results in resistance to therapies against a
single virus target (6, 19). The anti-HIV-1 sequences were
incorporated into U1 snRNA, a stable and abundant snRNA
molecule that functions in RNA processing (3, 23), to generate
U1/HIV antisense RNA. U1 snRNA transcripts are synthe-
sized in the nucleus and transported to the cytoplasm, where
they undergo modifications; after binding of specific proteins,
they are reimported to the nucleus, where they function with
other snRNPs in RNA splicing (23). Due to the central role in
RNA processing played by U1 snRNA, the U1 promoter is
expressed in all cell types. Approximately 106 copies of U1
RNA are transcribed from approximately 30 U1 genes per cell.
Each promoter thus transcribes an average of approximately
3 3 104 copies per generation (3).
We report here the results obtained by using independent
multitargeting U1/HIV antisense constructs to confer stable
HIV-1 resistance to CD41 cells.
MATERIALS AND METHODS
Construction of plasmids with antisense sequences introduced into the tran-
script region of the U1 gene. The steps used are presented in Fig. 1. The U1 gene
used is derived from pHSD-4 (10). Four pairs of oligonucleotides, designated
HVA-1 and HVA-2, HVB-1 and HVB-2, HVC-1 and HVC-2, and HVD-1 and
HVD-2, were synthesized. Each pair was hybridized to form double-stranded
molecules containing termini compatible with the BclI and BspE1 ends produced
from restriction enzyme digestion of the U1 transcript region of the plasmid.
Sequence A was taken from the HIV-1 transactivation response region of the
HXB2 strain, a T-cell-tropic clone of isolate IIIB (2), sequence B was taken from
the tat/rev exon of the LA1 strain, also a T-cell-tropic isolate (5), and sequence
C was taken from the tat/rev splice acceptor sequence of the BAL strain, a
monocytotropic isolate. Sequence D contains sequences unrelated to either U1
or HIV and serves as a negative control. Sequences of the oligonucleotides are
as follows: HVA-1, 59 GAT CCG GAT TGA GGC TTA AGC AGT GGG TTC
CCT AGT TAG CCA GAG AGC TCC CAG GCT CAG ATC TGG TCT AAT
39; HVA-2, 59 CCG GAT TAG ACC AGA TCT GAG CCT GGG AGC TCT
CTG GCT AAC TAG GGA ACC CAG TGC TTA AGC CTC AAT CCG 39;
HVB-1, GAT CCG GAC CTT GAG GAG GTC TTC GTC GCT GTC TCC
GCT TCT TCC TGC CAT AGG AGA GCC TAA GGT 39; HVB-2, 59 CCG
GAC CTT AGG CTC TCC TAT GGC AGG AAG AAG CGG AGA CAG
CGA CGA AGA CCT CCT CAA GGT CCG 39; HVC-1, 59 GAT CCG GAT
GGGAGG TGGGTC TGAAACGAT AATGGTGAG TAT CCC TGC CTA
ACT CTA TTC ACT AT 39; HVC-2, CCG GAT AGT GAA TAG AGT TAG
GCA GGG ATA CTC ACC ATT ATC GTT TCA GAC CCA CCT CCC ATC
CG 39; HVD-1, 59 GAT CAG CAT GCC TGC AGG TCG ACT CTA GAC
CCG GGT ACC GAG CTC GCC CTA TAG TGA GTC GTA TTA T 39; and
HVD-2, 59 CCG GAT AAT ACG ACT CAC TAT AGG GCG AGC TCG GTA
CCC GGG TCT AGA GTC GAC CTG CAG GCA TGC T 39.
BclI and BspE1 restriction enzyme digestion of pUC13 carrying the U1 operon
removes a 41-bp segment (bases 31 through 71) from the transcribed region of
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the U1 gene. Each of the hybridized oligomer pairs was inserted into the BclI/
BspE1 site created in the U1 transcript region of pHSD-4 to yield plasmids
designated pDU1A, pDU1B, pDU1C, and pDU1D. A segment carrying the
neomycin resistance gene was derived from pGK-neo (10) and introduced into
each plasmid (Fig. 1). The resulting plasmids were designated pNDU1A,
pNDU1B, pNDU1C, and pNDU1D. The three U1/HIV antisense cassettes de-
rived from pDU1A, pDU1B, and pDU1C were assembled into a single construct
(pNDU1A,B,C) as shown in Fig. 1.
U937 cells carrying U1/HIV antisense constructs. U937 cells (9) were trans-
fected with pNDU1A,B,C by the Lipofectin procedure (Bethesda Research
Laboratories [BRL]). The treated cells (53 105) were inoculated into T-25 flasks
(Corning) containing culture medium (Dulbecco modified Eagle medium; Gibco
and BRL) supplemented with 10% heat-inactivated fetal bovine serum (Gibco
and BRL) and 600 mg of G418 (Gibco and BRL) per ml. The G418-containing
medium was replaced every 3 to 4 days. The resulting population of G418-
resistant U937 cells was designated 2.10.16. Selection of a population of cells
carrying pNDU1D (designated 2.2.78) was done by using Lipofectin and enrich-
ment for G418 resistance as described above for 2.10.16.
PCR in situ hybridization for HIV-1 DNA sequences. PCR in situ hybridiza-
tion assays for U1/HIV antisense RNA were performed as described by Nuovo
et al. (14, 16). Cells obtained from the late stage of the growth phase were fixed
for 15 to 24 h in 10% buffered formalin and then washed twice in diethyl
pyrocarbonate-containing water. Approximately 5,000 cells were placed on a
silane-coated microscope slide and digested in 2 mg of pepsin per ml at 378C for
30 min. Assays for HIV-1 DNA were performed by using hot-start PCR (35
cycles) employing the gag primers SK38 and SK39 or SK145 and SK431 (nucle-
otides 1369 to 1395 and 1507 to 1481). PCR in situ hybridization for the provirus
was done with digoxigenin-labeled probes (SK19 and SK102) to assay for viral
entry after challenge.
In situ RT-PCR assay for U1/HIV antisense RNA sequence. The procedure
described above for in situ PCR detection of DNA was modified for specific
detection of U1/HIV antisense RNA sequences. Cells fixed to silane-coated glass
slides were protease treated and incubated overnight in RNase-free DNase
solution (10 U/section; Boehringer Mannheim) at 378C to eliminate nonspecific
DNA repair and mispriming. This allowed for target-specific direct incorporation
of digoxigenin-dUTP (used at a concentration of 10 mM in the reverse transcrip-
tion [RT]-PCR mix). Primers specific for U1/HIV antisense RNA sequences
were used. Assays for U1/HIV-1 RNA sequences used primer HU1, which
comprises a sequence from the transcript region of U1 (59-CCTGGCAGGGG
AGATACCATG-39), as the upstream primer and either HVA-2, HVB-2, or
HVC-2 as the downstream primer. For cells transfected with HVA, the HVB-2
and HVC-2 primers served as negative controls; similarly, for HVB transfectants,
HVA-2 and HVC-2 served as controls, and for HVC transfectants, HVA-2 and
HVB-2 served as negative controls. After protease and DNase digestion, RT and
PCR were accomplished by using an rTth EZ kit from Perkin-Elmer as previ-
ously reported (15). Pooled normal lymphocytes infected with HIV-1 isolate IIIB
for 4 days, and sham-infected cells (kindly provided by Roy Steigbigel, State
University of New York at Stony Brook) served as additional controls. The
negative and positive controls consistently yielded the expected results. The
signal is manifested as a blue precipitate due to the action of the antidigoxigenin-
alkaline phosphatase conjugate on the chromogen, nitroblue tetrazolium, and
the substrate, b-chloroindolylphosphate. Negative cells stained pink due to the
counterstain, nuclear fast red.
Assay for HIV-1 DNA. PCR was performed as described by Schnittman et al.
(18), using primer pairs SK38 and SK39 (gag). Reaction products were analyzed
by electrophoresis in 1.5% agarose in the presence of ethidium bromide. Com-
parisons were made with amplified DNA from U1.1A, a chronically infected
promonocyte cell line which contains two integrated HIV copies per cell (8).
U1.1A cells and U937 cells were mixed in various proportions so that in all
assays, DNA from 105 cells was analyzed.
Transient expression assays for the effect of U1/HIV antisense RNA on Tat-
activated expression of CAT. (i) Plasmids. The HIV-1 long terminal repeat-
chloramphenicol acetyltransferase (CAT) reporter construct pU3III-CAT was a
gift from Craig Rosen (17). The Tat plasmid pCV-1 contains a 1.8-kb fragment
of HIV-1 cDNA encompassing the tat gene (1).
(ii) DEAE-dextran transfection and CAT assay. In each transfection, 2.53 106
cells per condition were used. The cells were washed with serum-free RPMI 1640
(sfRPMI) and resuspended in 1 ml of sfRPMI containing 400 mg of DEAE-
dextran (Sigma) in 50 mM Tris-HCl (pH 7.3) with 2.5 mg of total plasmid per
condition. Cells were then incubated at 378C for 1 h, washed with sfRPMI,
resuspended in fresh culture medium, and incubated at 378C for 40 to 45 h. The
cells were harvested, washed, and resuspended in 100 ml of 0.25 M Tris-HCl (pH
7.8), and cell extracts were prepared by three cycles of freezing (dry ice-ethanol)
and thawing (378C water bath). Extracts were centrifuged, and the protein
content in the supernatants was estimated by using a micro bicinchoninic acid
reagent kit (Pierce, Rockford, Ill.).
(iii) CAT activity assay. CAT activity was determined by incubating 25 mg of
cell extracts with [14C]chloramphenicol (57.9 mCi/mmol; NEN) and 2.5 mM
acetyl coenzyme A (Pharmacia) at 378C for 2 h. Incubation was followed by
extraction with ethyl acetate and ascending thin-layer chromatography. Chro-
matograms were autoradiographed, and areas of radioactivity were cut out and
counted in scintillation fluid for quantification of CAT expression.
HIV-1 challenge assays. Cells (0.5 3 106 cells) were incubated with the BAL
or IIIB strain of HIV-1 at various multiplicities of infection (MOI, calculated
with perpheral mononuclear cells) in the presence of 2 mg of Polybrene per ml
for 2 h at 378C, using the procedure of Laurence et al. (9). The cells were then
washed and resuspended in 1 ml of culture medium (RPMI 1640 containing 10%
fetal bovine serum [Flow Laboratories] for U937 and the same components plus
G418 for all transfected cells). The cells were plated in duplicate (0.5 ml per
well). One half of the culture medium was removed and replaced with fresh
medium every 3 or 4 days. At intervals postinfection, samples of these cells were
tested for virus growth by assaying for p24 by enzyme-linked immunosorbent
antigen capture as instructed by the manufacturer (DuPont). Cells were also
tested for viability by using trypan blue dye exclusion. The levels of G418 used
had no effect on susceptibility of cells to infection or level of p24 antigen
produced.
RESULTS
Preparation of a multitargeting U1/HIV antisense con-
struct. HIV-1 antisense sequences were inserted into the U1
transcript sequence as depicted in Fig. 1A. The 41 bp removed
from the transcript region were replaced with the antisense
oligonucleotides sequences A (68 bp), B (62 bp), C (61 bp),
and D (63 bp). These insertions result in an increase of 27
bases in the length of the U1 transcript region of pDU1A, 21
bases in pDU1B, 20 bases in pDU1C, and 22 bases in pDU1D.
The effect of these replacements on U1 RNA structure was
assessed by the McDNASIS program (Hitachi, Inc.). The pre-
dicted secondary structures in all cases indicated that the in-
sertions do not alter the secondary structure of the 39 end; i.e.,
the U1/HIV antisense molecules are predicted to form normal
stem-loops III and IV as well as a normal Sm region.
In situ assays for U1/HIV antisense RNA in 2.10.16 cells
transfected with pNDU1A,B,C. To mimic more closely the
expected therapeutic use of these constructs, a pool of trans-
formed clones (designated 2.10.16) was obtained by transfec-
tion of U937 cells with plasmid pNDU1A,B,C and subsequent
enrichment of the transfected population for G418 resistance
(Materials and Methods). Figure 2 shows expression of the
U1/HIV antisense sequences in 2.10.16 as analyzed by in situ
amplification assay. These experiments used primers HU1-1
and HVA-2. Similar results were obtained when either HVB-2
or HVC-2 was used as the downstream primer. Note the nu-
clear localization of the dark blue precipitate indicative of the
PCR-amplified cDNA (Fig. 2D). Nuclear staining (hematoxy-
lin and eosin) indicates the large area of the cells occupied by
the nucleus (Fig. 2A). It is evident that 10 to 20% of the 2.10.16
cells express transcripts corresponding to the U1/HIV inserts
at a high enough level to be detected by this assay. 2.2.78 cells
(containing the control plasmid) showed no signal (Fig. 2C),
and omission of reverse transcriptase from the amplification
procedure resulted in no signal in 2.10.16 cells (Fig. 2E).
HIV challenge of 2.10.16 cells. The 2.10.16 cells were then
exposed to the BAL strain of HIV-1 at an MOI of 0.15. As can
be seen in Table 1 (challenge 1a), this pooled clone 2.10.16
showed resistance to HIV-1, as indicated by a reduction in p24
production compared to the control clones (either U937 or
FIG. 1. Insertion of antisense (AS) sequences into U1 operons. (A) Hybridization of the deoxyoligonucleotide (Oligo) pairs resulted in double-stranded molecules
with overhanging single-stranded termini compatible with the BclI and BspE1 ends produced from the restriction enzyme digestion of the U1 transcript region of the
plasmid. The resulting plasmids containing the inserts were designated pDU1A, pDU1B, pDU1C, and pDU1D. (B) Assembly of a DNA construct (pNDU1A,B,C)
containing three U1/HIV antisense cassettes.
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2.2.78) at 6 days postinfection. In another challenge experi-
ment (Table 1, challenge 1b), 2.10.16 cells showed greater than
90% inhibition of p24 production in the culture (compared
with parent U937 cells and 2.2.78 cells) at 16 days postinfec-
tion. Cell viability assays performed on day 24 postinfection by
using trypan blue exclusion showed that 17% of 2.2.78 pool
controls from challenge 1b were viable. The pooled clone
2.10.16 were 40 to 60% viable and had no visible syncytia (data
not shown).
At day 24, the 2.2.78 pool (which contains a DNA sequence
unrelated to either HIV-1 or U1 inserted into the U1 transcript
region [see Materials and Methods]) and the 2.10.16 cells were
subjected to Ficoll gradient separation to separate live cells
from dead cells, and the procedure was continued as a routine
maintenance procedure as necessary until day 35. At day 35,
there were no live cells remaining in the 2.2.78 culture.
Second challenge of 2.10.16 and U937 control cells. The
pooled clone population 2.10.16 taken from day 31 postinfec-
tion (now termed clone 2.10.16R1) and U937 control cells
(2.2.78) were subjected to a second challenge with the HIV-1
BAL strain at an MOI of 0.1. The cells were infected and
maintained as before. Results of p24 assays at days 9 and 12
FIG. 2. In situ RT-PCR assay for U1/HIV antisense RNA in 2.10.16 (unchallenged) and 2.10.16R2 (challenged) cells. (A) Nuclear staining shows the cytologic
features of the 2.10.16 cells after staining with hematoxylin and eosin. Note the large blue nucleus and the thin rim of pink cytoplasm. (B) In situ RT-PCR for U1/HIV
antisense sequence A in 2.10.16R2 (postchallenge) cells revealing a strong nuclear signal in all cells. (C) In situ RT-PCR for U1/HIV antisense sequence A in 2.2.78
cells. (D) In situ RT-PCR for U1/HIV antisense sequence A in 2.10.16 (prechallenge) cells. Note that a minority of the cells have a detectable nuclear signal. (E) In
situ RT-PCR for U1/HIV antisense sequence A in 2.10.16 cells when the reverse transcriptase treatment step is omitted.
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postinfection are presented in Table 2. At day 12 approxi-
mately 66% inhibition of p24 antigen production was observed
in 2.10.16R1 cells compared with U937 control cells. The cells
were then maintained with 3- to 4-day Ficoll separation of the
live from dead cells (as described above) until day 21. At this
time, 2.10.16R1 showed no evidence of p24 antigen and the
cells were 100% cell viable, as determined by trypan blue
staining (data not shown). In contrast, 2.2.78 control cells
(U937 control, Table 2) produced greater that 1,800 pg of p24
per ml, and parental U937 cells (not shown) weren’t viable.
Third challenge of 2.10.16 cells. In this experiment, the
pooled clone population identified as 2.10.16R1 from day 21 of
the second challenge experiment (now referred to as clone
2.10.16R2) was infected with the IIIB strain of HIV-1 as de-
scribed for the second challenge experiment. No p24 product
was obtained following exposure of 2.10.16R2 cells to an MOI
of 0.01, while high-level infection was seen in both parental
U937 cells and control 2.2.78 cells.
In situ RT-PCR assay for U1/HIV antisense RNA in 2.10.16R2
(postchallenge) cells. In situ RT-PCR performed on the
2.10.16R2 cells showed that over 90% of these cells expressed
U1/HIV antisense RNA at a detectable level (Fig. 2B), as
determined by using HU1-1 (see Materials and Methods) as
the upstream primer and either HVA-2 or HVC-2 as the down-
stream primer. Using HVB-2 or HVC-2 as the downstream
primer gave similar results. The production of U1/HIV anti-
sense in essentially all of the postchallenge cells is in contrast
to a detection rate of 10 to 20% in prechallenge cells (Fig. 2D).
Tat-activated expression in cells transfected with U1/HIV
antisense constructs. The effect of U1/HIV antisense con-
structs on Tat-activated expression was determined in transient
expression assays measuring Tat-activated expression of CAT
(see Materials and Methods). In unchallenged cells (Fig. 3A),
whether clone 2.10.16, which carries the multitargeting con-
struct pNDU1A,B,C), or any cells carrying the single targeting
constructs (4.12, 5.34, or 8.54, carrying HIV antisense se-
quence A, B, or C, respectively), expression was inhibited.
Postchallenge cells 2.10.16R2 (Fig. 3B) also demonstrated in-
hibition or Tat-activated CAT expression.
Assay for CD41 antigen of the surface of 2.10.16R2 cells. To
determine whether the 2.10.16R2 cells had retained the CD41
antigen, these cells were examined in flow cytometry after
treatment with mouse anti CD41 antibody (Leu-3a; Becton
Dickinson) and fluoresceinated goat anti-mouse (Tago). The
analysis showed that 45% of 2.10.16R2 cells contained CD41
antigen at a measurable level. This is equivalent to the 50 to
60% level normally observed in the parent U937 cells and
indicates that the observed resistance to HIV-1 cannot be
attributed to loss of the receptor protein CD41.
PCR assay for HIV-1 sequences in 2.10.16R2. Further evi-
dence that the virus is not present in this cell population re-
sulted from PCR assays for HIV nucleic acid. In assays using
DNA PCR (Perkin-Elmer) and the manufacturer’s primers
which recognize the gag coding region of the BAL strain of
HIV-1, no viral DNA was detected in 2.10.16R2 cells. As can
be seen in Fig. 4A, by using various numbers of untreated
U1.1A cells as a positive control, as few as 101 to 102 U1.1A
cells can be detected. However, amplification products of
DNA from 105 2.10.16R2 cells showed no HIV DNA. Simi-
larly, PCR in situ hybridization using primers specific for the
gag gene did not detect the provirus in any of the 2.10.16R2
cells. This is in contrast to a detection rate of over 90% in the
HIV-infected pooled lymphocytes (data not shown).
PCR assay for presence of the U1/HIV antisense construct
in 2.10.16R2 cells. 2.10.16R2 cells maintained for 60 days post-
challenge were assayed for the presence of the U1/HIV anti-
sense DNA by PCR assay. This assay used a primer pair rep-
resenting U1 transcript region sequences which occur on either
FIG. 3. Effect of U1/HIV antisense RNA on Tat-activated CAT expression.
Transient expression assays for CAT were performed as described in Materials
and Methods. Empty bars represent CAT expression in the absence of Tat; filled
bars represent CAT expression in the presence of Tat. (A) CAT activity in
prechallenge cells. The cell lines are described in the text. The 2.2.78 cells are
transfected with the control plasmid pNDU1D. (B) CAT activity in postchal-
lenge cells 2.10.16R2.
TABLE 1. HIV challenge of U937, 2.10.16, and 2.2.78 cells
Cells
p24 (pg/ml) % Viable cells,a
challenge 1b,
day 24
Challenge 1a,
day 6
Challenge 1b,
day 16
U937 959 200 0
2.10.16 pooled clones 514 (46.6b) 12 (94.5) 40–60
554 (42.2)
2.2.78 pool control 780 220 17
a Assayed by trypan blue staining assay.
b Percent difference in amount of p24/ml when the 2.10.16R1 cell supernatant
is compared with the supernatant from U937 cells.
TABLE 2. Second HIV challenge of 2.10.16R1 and
the parental U937 control cells
Cells
p24 (pg/ml)
Day 9 Day 12 Day 21
U937 control 3 5.1 .1,800
2.10.16R1 0 14.3 0
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side of the inserted antisense sequences. An amplicon derived
from the U1 sequence (without an insert) would be 179 bp in
length. An amplicon derived from U1 DNA with an inserted
HIV antisense sequence would be 206 bp for sequence A, 200
bp for sequence B, and 199 bp for sequence C, or 20, 21, and
27 bp longer than the U1 amplicon, respectively. Figure 4B
presents the results of amplification of 2.10.16R2 cells from
day 60 postchallenge (lane 1) and 2.10.16R1 cells from day 31
postchallenge (lane 2). DNA derived from these cells yields
two bands on electrophoresis (Fig. 4B). The upper band is
approximately 200 bp and is absent in U937 cells (which con-
tain no U1/HIV antisense sequences and only endogenous U1
gene sequences). The two bands are coincident with bands
produced from an equal mixture of DNAs from pNDU1A,B,C
and from pUC13 with the inserted U1 operon (lane P). These
data are consistent with the presence of the U1/HIV antisense
sequences in clones 2.10.16R1 and 2.10.16R2.
DISCUSSION
We report human HIV-1-resistant immune cells in culture
that show a high level of resistance to multiple challenges by
HIV for a prolonged period. During the challenge period,
these cells maintained viability, showed no evidence of latent
viral DNA, and retained their CD41 phenotype. These data
demonstrate that HIV-1-resistant CD41 cells can be devel-
oped by using U1/HIV antisense constructs.
Attempts have been made by others to use genetic antisense
constructs as a means of obtaining immune cells that are re-
sistant to HIV-1 by utilizing antisense sequences against one
specific HIV-1 target gene (2) or single RNA transcripts with
antisense sequences against more than one HIV-1 target. In
contrast to these studies, which showed a short period of
HIV-1 resistance followed by a period of virus growth and
ultimate cell destruction (6, 19), we have been successful in
conferring a stable, HIV-1 resistance to immune cells in cul-
ture by combining independent multitargeting with the use of
U1 snRNA as an antisense carrier.
The use of U1 snRNA provides a way to localize antisense
transcripts in the cell nucleus as a means for delivery of anti-
HIV antisense RNA to target sequences. While an active pop-
ulation of U1/antisense transcripts may be present in the cy-
toplasm at a concentration below the level of detection, the in
situ analyses presented herein indicate that a vast majority of
the U1/HIV antisense RNA is located in the nucleus. Nuclear
location could be advantageous for effectiveness since higher
concentrations of the antisense RNA can be maintained in the
smaller volume of the nucleus, interactions with mRNA can
occur prior to or during processing and translation, and there
would be no possibility of competition with messenger-binding
ribosomes. U1 snRNA also provides its inherent properties of
stability and high level of transcription. Furthermore, several
U1 antisense cassettes, each comprising approximately 750 bp,
can be incorporated into a single vector.
To retain U1 snRNA’s inherent properties for the delivery
of antisense sequences, we attempted to maintain the original
size as much as possible by using replacement of U1 sequences
with antisense sequences. The resulting increases were only 20,
21, and 27 bases to the three U1/HIV antisense constructs.
Although this substitution disrupts the formation of loops I
and II, which are responsible for binding of U1-specific pro-
teins, it allows exposure of the antisense sequences to potential
target RNA molecules. Also, insertion near the 59 end of the
transcript reduces the likelihood of disrupting secondary struc-
tures that may be critical for binding proteins that are respon-
sible for reimportation to the nucleus. In fact, computer pre-
dictions of secondary structures of the hybrid U1/HIV
antisense RNA molecules show no perturbation of the Sm
region or loops III and IV.
The U937 immune cells carrying U1/HIV antisense RNA
(2.10.16) were obtained as a cell population enriched for re-
sistance to G418. Since selection was made for G418, and not
for U1/HIV antisense expression, this population of cells
would be expected to contain cells that vary widely in antisense
expression. This variation in expression among clones has been
seen previously by Muller et al. (12) and by Szabo et al. (22),
who introduced foreign genes into U937 cells as part of con-
structs expressing G418 resistance. Thus, it is not surprising
that the first HIV-1 challenge resulted in virus growth in a
portion of the heterogeneous 2.10.16 cell population. Evidence
that this population is indeed heterogeneous is supported by in
situ RT-PCR assays which show that approximately 10 to 20%
of the cells produce detectable levels of each of the U1/HIV
antisense RNAs. HIV-1 replication was significantly reduced
in the second challenge, and during the third challenge no virus
growth was detected as indicated by p24 assay.
The development of this resistance to HIV-1 correlated with
the observation that essentially all 2.10.16R2 cells produced
U1/HIV antisense RNA, as shown by in situ analysis. Further
evidence that U1/HIV antisense RNA is responsible for this
HIV-1 resistance was provided by transient expression assays
for Tat-activated expression of CAT in 2.10.16R2 cells. Here,
2.10.16R2, compared with U937 cells and U937 cells carrying
a control construct (2.2.78), markedly inhibited Tat activated
expression.
Although the U1 antisense was designed to act in the nu-
cleus, the inability to detect provirus sequences in postchal-
lenge cells suggests the possibility that the U1/HIV antisense is
capable of acting in the cytoplasm prior to HIV-1 integration.
The presence of active antisense in the cytoplasm could result
from the natural kinetics of U1 processing (23) wherein the
U1/HIV antisense chimeric molecules are present in the cyto-
plasm prior to reimportation to the nucleus.
We have successfully achieved stable resistance to HIV in
human immune cells in culture. Independent multitargeting
was used to combat the variability and mutability of the virus.
This approach also provided independent expression of each of
the target sequences from an independent and specific pro-
FIG. 4. (A) PCR assay for HIV-1 gag in HIV-infected control cells and in
2.10.16R1 cells and 2.10.16R2 cells. The arrow indicates the HIV-1 gag amplicon
(147 bp). Lane 1, 102 U1.1A cells (promonocytic cells with two stably integrated
copies of HIV); lane 2, 103 U1.1A cells; lane 3, 104 U1.1A cells; lane 4, 105
U1.1A cells; lane 5, 104 2.10.16R1 cells (from day 31 after initial HIV infection);
lane 6, 105 2.10.16R2 cells (from day 60 after two challenges by HIV-1). (B) PCR
assay for the pNDU1A,B,C sequences. The arrow indicates the amplicon for
U1/HIV antisense sequences (199 to 206 bp). Lane P, amplification of a 1:1
mixture of DNA from pNDU1A,B,C and from pUC13 carrying the U1 operon;
lane 1, amplification of DNA from 2.10.16R2 cells from 60 days (after two HIV-1
challenges); lane 2, amplification of DNA from 2, 2.10.16R1 cells from 31 days
after the initial HIV-1 challenge; lane 3, amplification of DNA from U937 cells.
Lanes M contain molecular weight markers.
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moter, taking advantage of high rates of synthesis. The choice
of U1 as an antisense carrier provided structural stability and
nuclear localization. This successful approach in cell culture is
being developed as means of achieving a high level of stable
resistance in patient cells for the purpose of developing an ex
vivo therapy for treating HIV infections.
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